Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. The spectrum of NAFLD is broad, extending from simple steatosis through nonalcoholic steatohepatitis (NASH). Insulin resistance has been found to increase the risk of NASH, and obesity, and decreased levels of adiponectin are important factors in determining the severity of insulin resistance. Recent evidence has indicated that hypoadiponectinemia is involved in hepatic steatosis and NASH.


METHODS
To investigate whether hypoadiponectinemia causes hepatic steatosis in type 2 diabetes mellitus (DM) patients independently of visceral adipose tissue, we measured the plasma adiponectin concentration, hepatic fat content based on the liver-to-spleen ratio (L/S ratio) according to computed tomography (CT) attenuation values, and the amount of visceral adipose tissue and subcutaneous adipose tissue by CT in 248 type 2 DM patients. We also investigated the relationship between the serum level of adiponectin and hepatic fibrosis.


RESULTS
Significant correlations were observed between the L/S ratios and aspartate aminotransferase, alanine aminotransferase, visceral adipose tissue, subcutaneous adipose tissue, and serum adiponectin values (r=0.300, p=0.0007), and there was a highly significant inverse correlation between the visceral adipose tissue values and the serum adiponectin levels (r=-0.327, p<0.0002). The subcutaneous adipose tissue values, however, were not correlated with the serum adiponectin levels. Multiple regression analysis was used to quantify the impact of measured variables on the L/S ratio. After adjustment for age, gender, and visceral adipose tissue, the serum adiponectin levels were still significantly correlated with the L/S ratios (p=0.0064). And there was a stepwise decrease in the serum adiponectin in parallel to the severity of hepatic fibrosis.


CONCLUSIONS
Hypoadiponectinemia is concluded to be involved in the etiology of hepatic steatosis independently of visceral adipose tissue content, and is considered to be an important factor in the progression of fibrosis; further studies will be necessary to elucidate the exact physiological role of adiponectin and its contribution to the progression of NASH.
Yoneda
Masato
M
Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Iwasaki
Tomoyuki
T
Fujita
Koji
K
Kirikoshi
Hiroyuki
H
Inamori
Masahiko
M
Nozaki
Yuichi
Y
Maeyama
Shiro
S
Wada
Koichiro
K
Saito
Satoru
S
Terauchi
Yasuo
Y
Nakajima
Atsushi
A
D052242:Adiponectin / Q000097:blood; D000273:Adipose Tissue / Q000201:enzymology* / Q000473:pathology; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001823:Body Composition; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology* / Q000473:pathology; D005234:Fatty Liver / Q000201:enzymology* / Q000473:pathology; D005260:Female; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000473:pathology; D008103:Liver Cirrhosis / Q000201:enzymology / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D013154:Spleen / Q000201:enzymology / Q000473:pathology; D013223:Statistics as Topic; D014057:Tomography, X-Ray Computed
C499918:ADIPOQ protein, human; D052242:Adiponectin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase